| Long Non-Coding RNA (lncRNA) Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) Promotes Cell Proliferation and Migration by Regulating miR-143-3p and MAGE Family Member A9 (MAGEA9) in Oral Squamous Cell Carcinoma. | Long Non-Coding RNA (lncRNA) Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) Promotes Cell Proliferation and Migration by Regulating miR-143-3p and MAGE Family Member A9 (MAGEA9) in Oral Squamous Cell Carcinoma.
Yu L, Shao X, Huo L, Zhang T., Free PMC Article | 06/12/2021 |
| MAGE-A9 overexpression promoted cell proliferation, colony formation, migration, chemoresistance, and tumorigenicity in the context of EpCAM+ HCC cells, whereas MAGE-A9 knockdown significantly inhibited anchorage-dependent and spheroid colony formation and in vivo tumorigenicity. | High expression of MAGE-A9 contributes to stemness and malignancy of human hepatocellular carcinoma.
Wei Y, Wang Y, Gong J, Rao L, Wu Z, Nie T, Shi D, Zhang L. | 06/9/2018 |
| potential X-linked candidate for the CNV67-related spermatogenic failure phenotype | Evidence for the involvement of the proximal copy of the MAGEA9 gene in Xq28-linked CNV67 specific to spermatogenic failure.
Shen Y, Xu J, Yang X, Liu Y, Ma Y, Yang D, Dong Q, Yang Y. | 11/26/2017 |
| The overall survival of laryngeal squamous cell carcinoma patients with positive MAGE-A1, MAGE-A9, or MAGE-A11 expression was lower than the patients without MAGE-A1, MAGE-A9, or MAGE-A11 expression. | Expression of MAGE-A1, -A9, -A11 in laryngeal squamous cell carcinoma and their prognostic significance: a retrospective clinical study.
Liu S, Sang M, Xu Y, Gu L, Liu F, Shan B. | 01/14/2017 |
| High expression levels of MAGE-A9 are correlated with lung adenocarcinoma. | High expression levels of MAGE-A9 are correlated with unfavorable survival in lung adenocarcinoma.
Zhai X, Xu L, Zhang S, Zhu H, Mao G, Huang J., Free PMC Article | 11/5/2016 |
| The results showed that the high expression of MAGE-A9 protein in NSCLC tumor cells were commonly present in squamous cell carcinomas. It was also related to larger tumor diameter, lymph node metastasis and later stage grouping with TNM classification | High expression of MAGE-A9 in tumor and stromal cells of non-small cell lung cancer was correlated with patient poor survival.
Zhang S, Zhai X, Wang G, Feng J, Zhu H, Xu L, Mao G, Huang J., Free PMC Article | 12/19/2015 |
| These data are the first to indicate that MAGE-A9 expression is a valuable prognostic biomarker for HCC and that high MAGE-A9 expression suggests unfavorable survival outcomes in HCC patients | High expression of MAGE-A9 correlates with unfavorable survival in hepatocellular carcinoma.
Gu X, Fu M, Ge Z, Zhan F, Ding Y, Ni H, Zhang W, Zhu Y, Tang X, Xiong L, Li J, Qiu L, Mao Y, Zhu J., Free PMC Article | 11/7/2015 |
| High expression of MAGE-A9 indicates unfavorable survival outcome in laryngeal squamous cell carcinoma patients. | Expression and prognostic value of MAGE-A9 in laryngeal squamous cell carcinoma.
Han L, Jiang B, Wu H, Zhang S, Lu X., Free PMC Article | 07/25/2015 |
| The data suggest that MAGE-A9 expression is correlated with malignant attributes of invasive ductal breast cancer | Overexpression of MAGE-A9 predicts unfavorable outcome in breast cancer.
Xu X, Tang X, Lu M, Tang Q, Zhang H, Zhu H, Xu N, Zhang D, Xiong L, Mao Y, Zhu J. | 02/7/2015 |
| MAGE-A9 and MAGE-A11 are tumor-specific antigens and not only DNA hypermethylation but also histone deacetylation is responsible for the mechanism underlying MAGE-A9 and MAGE-A11 gene silencing. | Expressions of MAGE-A9 and MAGE-A11 in breast cancer and their expression mechanism.
Hou SY, Sang MX, Geng CZ, Liu WH, Lü WH, Xu YY, Shan BE. | 06/14/2014 |
| Overexpression of MAGE-A9 is associated with bladder cancer. | High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer.
Bergeron A, Picard V, LaRue H, Harel F, Hovington H, Lacombe L, Fradet Y. | 01/21/2010 |
| May provide suitable targets for immunotherapy of renal cell carcinoma. | Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-lymphocyte lines for transfer in patients with renal cell carcinoma.
Oehlrich N, Devitt G, Linnebacher M, Schwitalle Y, Grosskinski S, Stevanovic S, Zöller M. | 01/21/2010 |